Compare Supplements

Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.

Any time

Subcutaneous prefilled autoinjector (evolocumab)

Approved antihypertensive dosing is 20–80 mg once daily; the metabolic/PPARγ effects are most evident at the higher 80 mg (and study) doses, under a clinician. Not an approved metabolic or longevity regimen; blood pressure, kidney function, and potassium should be monitored.

Morning

Oral tablet (telmisartan)

• Prior serious hypersensitivity reaction to evolocumab
• Use only under clinician direction as part of a lipid-management plan

• Statins
• Ezetimibe

• Pregnancy (fetal harm)
• Bilateral renal artery stenosis
• Hyperkalemia

• ACE inhibitors (dual RAS blockade)
• Potassium-sparing diuretics / potassium / salt substitutes
• NSAIDs